Publicaciones en colaboración con investigadores/as de Hospital Infanta Leonor (20)

2023

  1. CD4/CD8 Ratio During Human Immunodeficiency Virus Treatment: Time for Routine Monitoring?

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Vol. 76, Núm. 9, pp. 1688-1696

  2. Comparison of the Fecal Bacteriome of HIV-Positive and HIV-Negative Older Adults

    Biomedicines, Vol. 11, Núm. 8

  3. Tenofovir Disoproxil Fumarate/Emtricitabine and Baricitinib for Patients at High Risk of Severe Coronavirus Disease 2019: The PANCOVID Randomized Clinical Trial

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Vol. 76, Núm. 3, pp. e116-e125

2022

  1. Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir/Abacavir/Lamivudine in Antiretroviral-Naive Adults (SYMTRI): A Multicenter Randomized Open-Label Study (PReEC/RIS-57)

    Open Forum Infectious Diseases

2021

  1. Recurring Severe Injection-Related Infections in People Who Inject Drugs and the Need for Safe Injection Sites in Madrid, Spain

    Open Forum Infectious Diseases, Vol. 8, Núm. 7

  2. Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19)

    Clinical Microbiology and Infection, Vol. 27, Núm. 2, pp. 244-252

2020

  1. Frailty, markers of immune activation and oxidative stress in HIV infected elderly

    PLoS ONE, Vol. 15, Núm. 3

  2. Gender-based vulnerability in women who inject drugs in a harm reduction setting

    PLoS ONE, Vol. 15, Núm. 3

  3. Sex Differences in People Aging With HIV

    Journal of acquired immune deficiency syndromes (1999), Vol. 83, Núm. 3, pp. 284-291

  4. Virological outcome among HIV infected patients transferred from pediatric care to adult units in Madrid, Spain (1997–2017)

    Scientific Reports, Vol. 10, Núm. 1

2019

  1. Frailty phenotype: A clinical marker of age acceleration in the older HIV-infected population

    Epigenomics, Vol. 11, Núm. 5, pp. 501-509

  2. High rates of early HCV reinfection after DAA treatment in people with recent drug use attended at mobile harm reduction units

    International Journal of Drug Policy, Vol. 72, pp. 181-188

2018

  1. HCV seroconversion in a cohort of people who use drugs followed in a mobile harm reduction unit in Madrid: Breaking barriers for HCV elimination

    PLoS ONE, Vol. 13, Núm. 10

  2. HIV in Spain 2017: Policies for a new management of chronicity beyond virological control

    Revista Espanola de Salud Publica, Vol. 92

  3. High HIV seroconversion rate in hepatitis C virus-infected drug users followed in a harm reduction unit: A lost opportunity for preexposure prophylaxis

    AIDS, Vol. 32, Núm. 9, pp. 1157-1163

2017

  1. Frailty and physical function in older HIV-infected adults

    Age and Ageing, Vol. 46, Núm. 3, pp. 522-526

  2. Simplification to dual therapy (atazanavir/ritonavir1lamivudine) versus standard triple therapy [atazanavir/ritonavir1two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study)

    Journal of Antimicrobial Chemotherapy, Vol. 72, Núm. 1, pp. 246-253

2016

  1. Abacavir/lamivudine plus rilpivirine is an effective and safe strategy for HIV-1 suppressed patients: 48 week results of the SIMRIKI retrospective study

    PLoS ONE, Vol. 11, Núm. 10

2015

  1. Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial

    The Lancet Infectious Diseases, Vol. 15, Núm. 7, pp. 775-784

  2. Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): A randomised, open-label, non-inferiority trial

    The Lancet Infectious Diseases, Vol. 15, Núm. 7, pp. 785-792